Sanofi lifts sales potential of blockbuster drug to USD 14.5bn

Sales of drug Dupixent, which is in direct competition with Danish firm Leo Pharma’s drug Adtralza, are going so well that the company behind the treatment, Sanofi, has raised its sales expectations to USD 14.5bn.

Photo: Violeta Santos Moura/Reuters/Ritzau Scanpix

When Paul Hudson, a British national, took over at the helm of French pharmaceutical company Sanofi back in June 2019, it was said that multi-blockbuster Dupixent could reach top sales of USD 11bn.

Since then, the drug has continued its explosive growth, and Sanofi is now lifting its sales ambitions for Dupixent to as much as USD 14.5bn, the company has announced in a press release ahead of an immunology investor event today, Tuesday, March 29.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs